BioCentury
ARTICLE | Company News

Ascend Biopharmaceuticals, Transgene deal

July 15, 2013 7:00 AM UTC

Transgene granted Ascend rights to develop and commercialize TG1042 ( ASN-002) to treat basal cell carcinoma, bladder cancer and an additional indication to be selected by Ascend. Transgene retains r...